User login
CHICAGO – Bevacizumab plus chemotherapy may extend the lives of women with recurrent metastatic cervical cancer, according to new study results presented at the American Society of Clinical Oncology. Compared with patients treated with chemotherapy alone, patients treated with chemotherapy plus bevacizumab had an improved median overall survival.
Dr. Krishnansu Tewari, who believes bevacizumab will be practice changing, presented the trial results at the annual meeting of the American Society of Clinical Oncology.
CHICAGO – Bevacizumab plus chemotherapy may extend the lives of women with recurrent metastatic cervical cancer, according to new study results presented at the American Society of Clinical Oncology. Compared with patients treated with chemotherapy alone, patients treated with chemotherapy plus bevacizumab had an improved median overall survival.
Dr. Krishnansu Tewari, who believes bevacizumab will be practice changing, presented the trial results at the annual meeting of the American Society of Clinical Oncology.
CHICAGO – Bevacizumab plus chemotherapy may extend the lives of women with recurrent metastatic cervical cancer, according to new study results presented at the American Society of Clinical Oncology. Compared with patients treated with chemotherapy alone, patients treated with chemotherapy plus bevacizumab had an improved median overall survival.
Dr. Krishnansu Tewari, who believes bevacizumab will be practice changing, presented the trial results at the annual meeting of the American Society of Clinical Oncology.
AT THE ASCO ANNUAL MEETING 2013